Search company, investor...
Kolon TissueGene company logo

Kolon TissueGene

Founded Year



Unattributed - III | Alive

Total Raised


Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+30 points in the past 30 days

About Kolon TissueGene

Kolon TissueGene is a biopharmaceutical company that focuses on developing regenerative therapies for the treatment of various orthopedic disorders. Kolon TissueGene was formerly known as TissueGene. The company was founded in 1999 and is based in Rockville, Maryland.

Headquarters Location

9713 Key West Ave. Suite 300

Rockville, Maryland, 20850,

United States


Missing: Kolon TissueGene's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Kolon TissueGene's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Kolon TissueGene

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kolon TissueGene is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Kolon TissueGene Patents

Kolon TissueGene has filed 10 patents.

The 3 most popular patent topics include:

  • Rare diseases
  • Biotechnology
  • Molecular biology
patents chart

Application Date

Grant Date


Related Topics




Rare diseases, Skeletal disorders, Orthopedic surgical procedures, Inflammations, Patellidae


Application Date


Grant Date



Related Topics

Rare diseases, Skeletal disorders, Orthopedic surgical procedures, Inflammations, Patellidae



Latest Kolon TissueGene News

CAR T-Cell Therapy Market Size to Expand USD 6.43 Bn by 2032

Jan 17, 2023

By end user, the hospitals segment has generated the revenue share of 61% in 2022. By indication, the lymphoma segment has captured 37% revenue share in 2022. By drug type, Axicabtagene Ciloleucel segment has held largest revenue share of 42% in 2022. Recent Developments In October 2019 - Novartis, which is a pharmaceutical industry, has its headquarter in Switzerland. It landed into a five-year collaboration with Microsoft, which is a technology company in the United States. Its aim is to develop and introduce the addition of its artificial intelligence services for enhancing the CAR T cancer therapy. Covid 19 impact During the COVID-19 pandemic, the supply chain was disrupted, and business operations were halted, leaving many life-science and biopharma companies waiting for new raw materials for CAR T-cell production. The lockdown hampered life science and biopharmaceutical production activities due to a lack of human resources, limiting the growth of the end-user segment market. This, however, was a temporary effect, and steady growth is expected in the coming years as the situation normalizes. Ask here for more customization study@ Scope of the Report Key Players Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., MEDIPOST, PHARMICELL Co., Ltd., ANTEROGEN. CO., LTD, Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences, Inc., Curocell, Inc., JW Therapeutics (Shanghai) Co., Ltd., Stempeutics Research PVT LTD and Others Market Dynamics An increasing number of CAR-T cell therapy product approvals. Increased awareness of the innovative approach to cancer therapy leads to increased demand for CAR-T cell therapy supplies. As a result, the market's key players are developing new products, driving the development of the global CAR-T cell industry. For instance, Kite Pharma received approval from the European Medicines Agency in June 2020 to implement a variation to the Yescarta (axicabtagene ciloleucel) marketing authorization for end-to-end manufacturing. Restraint The high cost of therapy The production of CAR-T cells for a single patient may cost up to $40,000, although it is too soon to determine the actual amounts. Such costs are incurred due to the requirement for sophisticated manufacturing facilities, highly trained personnel, costly materials, and assurance of biosafety and quality. On the other hand, the commercial costs of CAR-T cell therapy are estimated to be much higher than those of CAR-T cell production, likely ten times or more. Furthermore, when calculating the total cost of CAR-T cell therapy, one must consider expenses such as hospitalization and the co-administration of other agents or drugs with CAR-T cells. Nevertheless, despite being a costly therapeutic approach, its potential economic benefits for patients and society must be considered. Segments Insights Drug Type Snapshot In 2022, axicabtagene ciloleucel ruled the global CAR T-cell therapy industry, and this progress is predicted to continue throughout the estimated period. During the projected period, the need for Yescarta in the diagnosis of follicular lymphoma and diffuse large B-cell lymphoma is estimated to drive segment growth. On the other hand, Tisagenlecleucel was the largest segment in 2022. The segment is anticipated to be driven by the rising need for Kymriah to cure acute lymphoblastic lymphoma and the approval of products in various countries. Indication Snapshot The lymphoma segment is the market leader, predicted to expand during the projected period due to an increase in non-Hodgkin lymphoma cases. According to the WHO, nearly 544,352 new non-Hodgkin lymphoma cases were diagnosed worldwide in 2020. Furthermore, the increasing number of the elderly, more vulnerable to such ailments, is driving segment expansion. On the other hand, chronic lymphocytic leukemia is anticipated to grow at a steady pace. The most familiar type of leukemia, chronic lymphocytic leukemia (CLL), accounts for more than one-third (37%) of all newly diagnosed leukemia cases in the US. The American Cancer Society states that there were 21,040 new cases of CLL and 4,060 deaths from CLL in the United States in 2020. End-user Snapshot In terms of revenue, the hospital segment ruled the global CAR T-cell therapy industry in 2022. Cancer treatment hospitalization is projected to drive hospital growth. The segment is being propelled forward by the growing global oncology burden caused by increased alcohol and tobacco consumption. The cancer treatment center segment is expected to grow the fastest during the projected period. The cancer treatment center segment is being propelled forward due to the availability of advanced and sophisticated instruments required for cancer treatment. Regional Snapshot The Asia Pacific CAR T-cell therapy industry is expected to increase from 2023 to 2032. This can be attributed to developing countries with commercial hubs, the development of corporate organizations, and the increased awareness regarding regenerative medicine. On the other hand, Europe is expected to grow steadily due to government initiatives to assist the poor. Germany's CAR T-cell treatment industry is predicted to develop fastest. Growth is being fueled by rapid development and rising investment. Spain is the first country to receive approval for a CAR T-cell therapy entirely developed in Europe. It is approved for patients over the age of 25 who has acute lymphoblastic leukemia (a type of blood and bone marrow cancer) using a monoclonal antibody developed at the hospital clinic de Barcelona more than 30 years ago. Immediate Delivery Available | Buy this Premium Research Report@ You can place an order or ask any questions, please feel free to contact at   | +1 9197 992 333 About Us Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. For Latest Update Follow Us:

Kolon TissueGene Frequently Asked Questions (FAQ)

  • When was Kolon TissueGene founded?

    Kolon TissueGene was founded in 1999.

  • Where is Kolon TissueGene's headquarters?

    Kolon TissueGene's headquarters is located at 9713 Key West Ave., Rockville.

  • What is Kolon TissueGene's latest funding round?

    Kolon TissueGene's latest funding round is Unattributed - III.

  • How much did Kolon TissueGene raise?

    Kolon TissueGene raised a total of $64.72M.

  • Who are the investors of Kolon TissueGene?

    Investors of Kolon TissueGene include Maryland Technology Development Corporation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.